CLINICAL TRIALS PROFILE FOR SAREDUTANT

Clinical Trials for Saredutant

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00250601 ↗	An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression	Completed	Sanofi	Phase 3	The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with depression. The secondary objectives are to evaluate the safety of saredutant, to evaluate the efficacy of saredutant on disability and quality of life in patients with depression, and to evaluate blood levels of saredutant.
NCT00250614 ↗	An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression	Completed	Sanofi	Phase 3	The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with depression. The secondary objectives are to evaluate the safety of saredutant, to evaluate the efficacy of saredutant on disability and quality of life in patients with depression, and to evaluate blood levels of saredutant.
NCT00250627 ↗	An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression	Completed	Sanofi	Phase 3	The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with depression. The secondary objectives are to evaluate the safety of saredutant, to evaluate the efficacy of saredutant on disability and quality of life in patients with depression, and to evaluate blood levels of saredutant.
NCT00250653 ↗	A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression	Completed	Sanofi	Phase 3	The purpose of the study is to evaluate the long-term safety of saredutant (or SR48968C) in adult and elderly patients with depression.The primary objective is to evaluate the long-term safety and tolerability of a 100 mg dose of saredutant in adult and elderly patients with depression. The secondary objective is to evaluate blood levels of saredutant.
NCT00256113 ↗	An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression	Completed	Sanofi	Phase 3	The purpose of the study is to evaluate the efficacy and safety of saredutant (or SR48968C) in patients with depression. The primary objective is to evaluate the efficacy of a 100 mg dose of saredutant compared to placebo in patients with depression. The secondary objectives are to evaluate the safety of saredutant, to evaluate the efficacy of saredutant on disability and quality of life in patients with depression, and to evaluate blood levels of saredutant.
NCT00336713 ↗	A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)	Completed	Sanofi	Phase 3	The purpose of the study is to evaluate the long-term efficacy and safety of Saredutant in patients with depression. The primary objective is to evaluate the efficacy and safety of Saredutant 100 mg once daily compared to placebo in the prevention of relapse of depressive symptoms in outpatients with major depressive disorder who achieved an initial response to 12 weeks of open-label treatment with Saredutant.
NCT00390533 ↗	An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder	Completed	Sanofi	Phase 3	The primary objective is to evaluate the efficacy of two fixed doses (100 mg and 30 mg once daily) of saredutant compared to placebo in patients with generalized anxiety disorder. The secondary objectives are to evaluate the efficacy of saredutant on disability and quality of life in patients with generalized anxiety disorder, and to evaluate blood levels of saredutant.

Clinical Trial Conditions for Saredutant

Condition Name

Condition Name
Intervention	Trials
Depressive Disorder	8
Generalized Anxiety	2
Major Depressive Disorder	1
Anxiety	1

Condition MeSH

Condition MeSH
Intervention	Trials
Depressive Disorder	10
Depression	10
Disease	3
Depressive Disorder, Major	3

Clinical Trial Locations for Saredutant

Trials by Country

Trials by Country
Location	Trials
United States	10
Mexico	5
France	4
Canada	4
Croatia	3

Trials by US State

Trials by US State
Location	Trials
New Jersey	9
Pennsylvania	1

Clinical Trial Progress for Saredutant

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	13

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	13

Clinical Trial Sponsors for Saredutant

Sponsor Name

Sponsor Name
Sponsor	Trials
Sanofi	13

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	13